- PBIO
expects to achieve a significant revenue increase in 2019 and beyond
through the expansion of its proprietary BaroFold platform into the
estimated $44 billion global bioprocess technology market
- Over
200 therapeutic proteins and peptides are currently approved by the FDA
for use with conditions such as cancer, immunological and metabolic
disorders and infectious diseases
- Hundreds
of additional protein and peptide-based drugs are in development worldwide
- PBIO’s
proprietary BaroFold platform offers a unique and cost-effective way to
address two of the most complex and challenging issues critical to the
development and manufacture of therapeutic proteins
Pressure BioSciences Inc. (OTCQB: PBIO), a leader in the
development and sale of innovative, broadly enabling, pressure-based
technologies and products to the worldwide life sciences and other industries,
recently announced its execution of a contract services agreement with a
world-renowned, multibillion-dollar biotherapeutics firm. Under the terms of
the agreement, the firm will utilize PBIO’s proprietary BaroFold(TM) technology
platform to enhance the process manufacturing of one of its candidate protein
drugs (http://ibn.fm/aidN2).
PBIO’s BaroFold technology platform offers a unique and
cost-effective way to address the complex and often challenging process of
manufacturing the recombinant proteins that are required in the development of
protein-based drugs. Two of the major challenges associated with manufacturing
recombinant proteins are (1) the formation of aggregates and (2) protein
misfolding. These are significant issues that can prevent a protein drug
candidate from ever making it to market.
“The BaroFold platform can be applied to the development and
production of many different therapeutic proteins, can improve product safety,
and is scalable and practical for standard bioprocess environments,” Dr.
Alexander Lazarev, PBIO’s chief science officer, stated in a news release. “Moreover,
it offers ways to reduce or eliminate the use of aggressive chemicals in the
protein manufacturing process. We believe this unique technology platform can
help biopharmaceutical companies create and manufacture high quality novel
protein therapeutics and biosimilars, lower the cost of existing formulations,
and help protect our environment.”
Protein-based therapeutics are a large and growing part of
the global health care industry. Based on data in the THPdb database (http://ibn.fm/0TGzt), there are
over 200 therapeutic proteins and peptides currently approved by the FDA for
clinical use in the United States. These target therapies have shown
significantly improved outcomes for many patients suffering from severe medical
conditions, such as cancer and immunological diseases. The global protein drug
market is projected to reach nearly $249 billion by 2020 at a compound annual
growth rate of 7.3 percent from 2015 to 2020, according to data from Research and
Markets (http://ibn.fm/i4Pu7).
PBIO’s recently launched Biopharma Services Business – based
on its patented BaroFold technology platform – also provides the company with a
unique opportunity to enter the global bioprocess technology market, which
Transparency Market Research expects to be valued at an estimated $44 billion
by 2026 (http://ibn.fm/aPMP0).
“In addition to successfully performing contract services
for two biopharmaceutical companies since the beginning of 2019, we are also in
discussions with three additional bio-therapeutic companies interested in
utilizing our proprietary BaroFold services for their protein drug candidates,”
Richard T. Schumacher, president and CEO of PBIO, stated in a news release. “To
take full advantage of this opportunity, we have doubled the capacity of our
contract services team, purchased additional sophisticated equipment, and
developed new high-pressure concepts that further improve and enhance our
BaroFold process scalability and its GMP compliance.”
“We believe our recently launched Biopharma Services
Business could add as much as $500,000 to 2019 total revenue and significantly
more to total revenue for 2020 and beyond,” Schumacher concluded. “It is
important to note that these estimates do not include the anticipated growth in
Barocycler 2320EXT sales that we believe will result from biotechnology and
biopharmaceutical companies developing their own manufacturing, quality
control, and protein characterization applications on our leading PCT-based
instrument system.”
In addition to its new Biopharma Services Business, the
company develops and markets high-pressure instruments for scientific research
purposes throughout the United States, Canada, Europe, Australia and Asia. To
date, PBIO has installed approximately 350 pressure cycling technology (PCT)
systems (Barocycler, Barozyme, HUB) in nearly 200 leading academic, government,
biotech and pharma laboratories around the world, while its PCT platform
continues to be prominently featured in a record number of international
science conferences (http://ibn.fm/hSPKV).
The company recently announced that it will be entering the
rapidly growing CBD market with its newly designed BaroShear K45 instrument.
Based on its proprietary Ultra Shear Technology (UST) platform, the company
believes that BaroShear K45 sales in 2020 will result in a doubling of current
2019 revenue. Besides the CBD market, this revolutionary processing system is
also expected to attract customers spanning multiple markets, including
pharmaceuticals, cosmetics, nutraceuticals, food and beverage, and more.
For more information, visit the company’s website at www.PressureBioSciences.com
NOTE TO INVESTORS: The latest news and updates
relating to PBIO are available in the company’s newsroom at http://ibn.fm/PBIO
About MissionIR
MissionIR is
primarily focused on strategic communications. We have executed countless
communications programs to address the needs of companies ranging from
start-ups to established industry leaders, gaining valuable experience and the
expertise necessary to determine the most effective strategy for any given
situation.
For more information, visit www.MissionIR.com
Please see full terms of use and disclaimers on the Mission
Investor Relations website applicable to all content provided by MIR, wherever
published or re-published: http://www.missionir.com/disclaimer.html
